Table 1 Multiple OVs for the treatment of head and neck cancers in clinical trials
From: A review on the advances and challenges of immunotherapy for head and neck cancer
Virus family | Oncolytic agent | Phase | Administration route | Combination with | ClinicalTrials.gov ID |
|---|---|---|---|---|---|
Measles virus | MV-NIS | I | IT | No | NCT01846091 |
HSV-1 | HF10 | I | IT | No | NCT01017185 |
Adenovirus | CAdVEC | I | IT | CAR-T cell | NCT03740256 |
Coxsackievirus 21 | CAVATAK | I | IT | No | NCT00832559 |
Reovirus | Reolysin | II | IV | Paclitaxel/Carboplatin | NCT00753038 |
Reovirus | Reolysin | III | IV | Paclitaxel/Carboplatin | NCT01166542 |
HSV-1 | ONCR-177 | I | IT | Pembrolizumab | NCT04348916 |
Vaccinia virus | GL-ONC1 | I | IV | Radiotherapy/Cisplatin | NCT01584284 |
VSV | VSV-IFNβ-NIS | I/II | IV | Pembrolizumab | NCT03647163 |
Adenovirus | VCN-01 | I | IV | Durvalumab | NCT03799744 |
Adenovirus | OBP-301 | II | IT | Pembrolizumab/SBRT | NCT04685499 |
Vaccinia virus | JX-594 | I | IT | No | NCT00625456 |